Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Euphorbia Kansui Tea in HIV-infected ART-Suppressed Individuals
NCT02531295Phase 1Terminated
- Sponsor
- University of California, San Francisco
- Start
- May 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of euphorbia kansui extract in human immunodeficiency virus infection (HIV) (3 arms), sponsored by University of California, San Francisco. Primary endpoint: Safety of Euphorbia Kansui Extract Powder Prepared as Tea at 31 days. Started May 2019; status: terminated.
02
Drugs
euphorbia kansui extract
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02531295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531295.